Toxicity and teratogenicity studies with the hypolipidemic drug RMI 14,514 in rats.
The hypolipidemic drug RMI 14,514 (5-tetradecyloxy-2-furoic acid) has an oral LD50 of over 5000 mg/kg in rats. In a chronic toxicity study (6 months drug diet) doses of 30, 100, or 300 mg/kg/day produced no obvious signs of toxicity or abnormal clinical pathology parameters, other than prominent growth retardation at 300 mg/kg, which was somewhat alleviated when the dose was reduced to 200 mg/kg after 6 weeks. Hepatic change in the form of mild lipid accumulation was noted histopathologically after 6 months of treatment at 100 or 300 mg/kg/day, but was not present at 3 months or after 4 weeks off drug. The administration of RMI 14,514 in the diet to pregnant rats at 30, 100, or 150 mg/kg/day on Days 7 thru 21 of pregnancy (day 1 = day sperm detected) did not induce any teratogenic effects. When rats were exposed to the drug from implantation thru sexual maturity (126 days of age) at the same dosage, it produced no adverse developmental or behavioral effects, except for slight reduction in weight gain from birth to sexual maturity at 150 mg/kg/day. The drug caused reductions in plasma cholesterol and total fatty acids, but no distinct changes in various tissue lipids, except in the erythrocyte where fatty acids and phospholipids were reduced. These differences did not affect membrane integrity of the erythrocyte as far as osmotic or mechanical fragility tests could determine. The drug, which bears a structural resemblance to long-chain fatty acids, was incorporated into tissue lipids in detectable amounts, but tended to disappear from tissues at a rate similar to that of expected lipid turnover after treatment was stopped.